CARA insider trading

Cara Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
326
Last 90 days
0
Buys / sells
2% / 56%
Market cap

CARA insider activity at a glance

FilingIQ has scored 326 insider transactions for CARA since May 15, 2015. The most recent filing in our index is dated Feb 28, 2025.

Across the full history, 5 open-market purchases and 184 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CARA insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest CARA Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Frequently asked

How many insider trades does FilingIQ track for CARA?
FilingIQ tracks 326 Form 4 insider transactions for CARA (Cara Therapeutics, Inc.), covering filings from May 15, 2015 onwards. 0 of those were filed in the last 90 days.
Are CARA insiders net buyers or net sellers?
Across the full Form 4 history for CARA, 5 transactions (2%) were open-market purchases and 184 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CARA insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

Methodology & sources

Every CARA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.